Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy

Clinical Microbiology and Infection

Volumn 18, Issue 3, 2012, Pages

  Franzetti, M ^a,j   Violin, M ^a,j   Casazza, G ^b   Meini, G ^c   Callegaro, A ^d   Corsi, P ^e   Maggiolo, F ^d   Pignataro, A R ^f   Paolucci, S ^g   Gianotti, N ^f   Francisci, D ^h   Rossotti, R ⁱ   Filice, G ^g   Carli, T ^j   Zazzi, M ^c   Balotta, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ A MANZONI HOSPITAL   (Italy)

^j MISERICORDIA HOSPITAL   (Italy)

more..

Author keywords

Antiretroviral treatment; Drug resistance; HIV 1; HIV 1 evolution; Non B subtypes

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; TREATMENT RESPONSE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84857656362     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03740.x     Document Type: Article

References (20)

1. Monno L, Brindicci G, Lo Caputo S et al. HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. J Med Virol 2005; 75: 483-490.
2. Balotta C, Facchi G, Violin M et al. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr 2001; 27: 499-505.
3. Lai A, Riva C, Marconi A et al. Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. HIV Med 2010; 11: 593-602.
4. Baldanti F, Paolucci S, Ravasi G et al. Changes in circulation of B and non-B HIV strains: spotlight on a reference centre for infectious diseases in northern Italy. J Med Virol 2008; 80: 947-952.
5. Riva C, Lai A, Caramma I et al. Transmitted HIV type 1 drug resistance and non-B subtype prevalence among seroconverters and newly diagnosed patients from 1992 to 2005 in Italy. AIDS Res Hum Retroviruses 2010; 26: 41-49.
6. Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16: 1139-1146.
7. Atlas A, Granath F, Lindstrom A et al. Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy. AIDS Res Hum Retroviruses 2005; 21: 221-227.
8. De Wit S, Boulme′ R, Poll B et al. Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients. AIDS 2004; 18: 2330-2331.
9. Bocket L, Cheret A, Deuffic-Burban S et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antiviral Ther 2005; 10: 247-254.
10. Bannister WP, Ruiz L, Loveday C et al. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antiviral Ther 2006; 11: 707-715.
11. Cassol E, Page T, Mosam A et al. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. J Infect Dis 2005; 191: 324-332.
12. Garrido C, Zahonero N, Fernandes D et al. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother 2008; 61: 694-698.
13. Geretti AM, Harrison L, Green H et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48: 1296-1305.
14. Easterbrook PJ, Smith M, Mullen J et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 2010; 13: 4.
15. Kantor R, Katzenstein DA, Efron B et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2: 325-337.
16. Monno L, Scudeller L, Brindicci G et al. Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects. Antiviral Res 2009; 83: 118-126.
17. Shahriar R, Rhee SY, Liu TF et al. Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob Agents Chemother 2009; 53: 4869-4878.
18. Bandaranayake RM, Kolli M, King NM et al. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways. J Virol 2010; 84: 9995-10003.
19. Snoeck J, Kantor R, Shafer RW et al. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006; 50: 694-701.
20. Camacho RJ, Vandamme AM. Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation. Curr Opin HIV AIDS 2007; 2: 123-129.